Evidence map›Paper›PMID 27911847›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Zika virus cell tropism in the developing human brain and inhibition by azithromycin.

Hanna Retallack, Elizabeth Di Lullo, Carolina Arias, Kristeene A Knopp, Matthew T Laurie, Carmen Sandoval-Espinosa, Walter R Mancia Leon, Robert Krencik, Erik M Ullian, Julien Spatazza and 5 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04349592 (Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19), which is not on this map. Cited by 298 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
298citing papers in PubMed, 5 pooled it
53.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04349592 nacompletednot on this mapstarted 2020, after this paper: background citation

Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

TypeinterventionalSponsorHamad Medical CorporationRan2020 to 2020Enrolled456ConditionsCovid19ArmsHydroxychloroquine, Azithromycin, Placebo Tablet, Placebo capsules
3 · Its place in the literature

Who cites it

298 citing papers in PubMed, 5 syntheses or guidelines pooled it, 509 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Reduction of Coronavirus Burden With Mass Azithromycin Distribution.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Arboviruses in Cancer therapy: pros and cons.Journal of neurovirology · 2026
    Review
  13. Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

238 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Hanna RetallackDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158.
Elizabeth Di LulloEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143.
Carolina AriasDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158.
Kristeene A KnoppDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158.
Matthew T LaurieDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158.
Carmen Sandoval-EspinosaEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143.
Walter R Mancia LeonEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143.
Robert KrencikDepartment of Ophthalmology, University of California, San Francisco, CA 94122.
Erik M UllianDepartment of Ophthalmology, University of California, San Francisco, CA 94122.
Julien SpatazzaEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143.
Alex A PollenEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143.
Caleigh Mandel-BrehmDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158.
Tomasz J NowakowskiEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143.
Arnold R KriegsteinEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA 94143; kriegsteina@stemcell.ucsf.edu joe@derisilab.ucsf.edu.
Joseph L DeRisiDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158; kriegsteina@stemcell.ucsf.edu joe@derisilab.ucsf.edu.
University of California, San Francisco · USBroad Center · USNeurological Surgery · USUniversity of California, Santa Barbara · US

Funding

Development and Expansion of the Human Cerebral CortexR35NS097305 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRIEGSTEIN, ARNOLD · 2017 to 2024
$8.5M
Microbial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5M
Mapping the Developing Human Neocortex by Massively Parallel Single Cell AnalysisU01MH105989 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRIEGSTEIN, ARNOLD · 2014 to 2016
$5.1M
Stem Cells of the Developing Human NeocortexR01NS075998 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRIEGSTEIN, ARNOLD · 2011 to 2016
$1.8M
Investigating Astrocyte Diversity and Function in Midbrain Dopaminergic CircuitsR01MH099595 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ULLIAN, ERIK M · 2013 to 2015
$826k
Howard Hughes Medical InstituteNIAID NIH HHS T32 AI060537NIMH NIH HHS R01 MH099595NIMH NIH HHS U01 MH105989NINDS NIH HHS R01 NS075998NINDS NIH HHS R35 NS097305
6 · The paper itself

Abstract

The rapid spread of Zika virus (ZIKV) and its association with abnormal brain development constitute a global health emergency. Congenital ZIKV infection produces a range of mild to severe pathologies, including microcephaly. To understand the pathophysiology of ZIKV infection, we used models of the developing brain that faithfully recapitulate the tissue architecture in early to midgestation. We identify the brain cell populations that are most susceptible to ZIKV infection in primary human tissue, provide evidence for a mechanism of viral entry, and show that a commonly used antibiotic protects cultured brain cells by reducing viral proliferation. In the brain, ZIKV preferentially infected neural stem cells, astrocytes, oligodendrocyte precursor cells, and microglia, whereas neurons were less susceptible to infection. These findings suggest mechanisms for microcephaly and other pathologic features of infants with congenital ZIKV infection that are not explained by neural stem cell infection alone, such as calcifications in the cortical plate. Furthermore, we find that blocking the glia-enriched putative viral entry receptor AXL reduced ZIKV infection of astrocytes in vitro, and genetic knockdown of AXL in a glial cell line nearly abolished infection. Finally, we evaluate 2,177 compounds, focusing on drugs safe in pregnancy. We show that the macrolide antibiotic azithromycin reduced viral proliferation and virus-induced cytopathic effects in glial cell lines and human astrocytes. Our characterization of infection in the developing human brain clarifies the pathogenesis of congenital ZIKV infection and provides the basis for investigating possible therapeutic strategies to safely alleviate or prevent the most severe consequences of the epidemic.

Indexed as

Axl Receptor Tyrosine KinaseAzithromycinBrainCell LineCytopathogenic Effect, ViralFemaleHumansInfant, NewbornMicrobial Sensitivity TestsMicrocephalyNeurogliaPregnancyProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesViral TropismVirus InternalizationAxl Receptor Tyrosine KinaseAzithromycinProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinasesazithromycincortical developmentmicrocephalyZika virus

Identifiers

PMID27911847
PMCPMC5167169
OpenAlexW2558875419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.